All News

This is the second in a bimonthly series aimed at educating physicians on the pertinent aspects of litigation. Each case study will provide analysis of an actual ob/gyn lawsuit defended by the New York firm of Aaronson, Rappaport, Feinstein & Deutsch, LLP.

SMFM's Practice Committee reviews the scientific evidence on antenatal steroids and offers its recommendations on rescue and repeat courses of treatment.

To prevent pernatal infection, the latest CDC recommendtions emphasize the need for universal culture-based screening for pregnant women.

Although controversial, delivery is usually recommended for all women with severe preeclampsia--regardless of gestational age. But premature delivery can pose a major threat to the periviable fetus. When is it appropriate to expectantly manage severe preeclampsia?

Despite national progress towards ensuring that more pregnant women receive early prenatal care, many birth outcomes are not improving.

Part 3: Diseases characterized by genital ulcers.

Cardiac disease is one of the leading causes of maternal mortality during pregnancy. And because symptoms may mimic those of pregnancy, the diagnosis can be missed. Two experts tell how to minimize common complications.

Will heparin prevent adverse pregnancy outcomes among women with thrombophilia? Can patients prone to clotting safely take OCs and HRT? The author's concluding article addresses these and related treatment issues.

No. The better question may be whether the cesarean rate is too low.

Yes. It could be lower but it is difficult to know whether it really should be lower.

The second excerpt for the new guidelines outlines the latest federal recommendations for detecting HIV infection and counseling patients who contract the disease.

While cervical incompetence is an important contributor to many preterm births before 28 weeks, cerclage is not always the appropriate remedy. Candidates should be selected with care and the procedure contemplated only after consideration of benefits and risks to both mother and fetus and in-depth patient counseling.

Ob/gyns can better identify patients prone to deep vein thrombosis and fetal loss by learning more about this group of disorders.

This is the first in a bimonthly series aimed at educating physicians on the pertinent aspects of litigation.

Even before Bethesda 2001 terminology recommended substantial changes in how labs should report Pap results--including specimen adequacy--many clinicians were confused about which patients to follow-up with repeat Pap tests. This article explains and clarifies the latest Pap test adequacy guidelines.

By helping Hispanic patients interact effectively with the health-care system, ob/gyns can increase the amount of prenatal care these women receive and decrease their high rates of preterm delivery and pregnancy-related maternal mortality.

This report updates the 2001 recommendations by the Advisory committee on Immunization Practices (ACIP) regarding the use of influenza vaccine and antiviral agents.

Multiple births related to infertility treatment have increased dramatically in recent years and are associated with significant personal, economic, and social costs.

No. The costs to the couple and to society are too high.

Ob/gyn patients undergo ultrasounds for a number of reasons. Because of the small variety of closely related U/S codes, successful billing for more than one U/S depends on the diagnosis and documentation.

Yes. Given the limitations of technology and our health-care system, twins are acceptable, if not desirable.

These guidelines for the treatment of patients who have sexually transmitted diseases (STDs) were developed by the Centers for Disease Control and Prevention.

While a single course of antenatal corticosteroids improves neonatal outcomes among infants born prematurely, the efficacy and safety of repetitive courses of ACS (including rescue dosing) is less clear. In the absence of adequate data to support a policy of repetitive dosing of ACS, such therapy should only be used as part of well-designed clinical trials.